AstraZeneca expands deal Vaccine Covid-19 in connection with the start of the final test

Illustrative vial of coronavirus vaccine

AstraZeneca has expanded an agreement with Oxford Biomedica to scale up production of its potential Covid-19 vaccine, as the race continues to find an effective prevention for the deadly virus.

Under the supply agreement, the Oxford-based cell and gene therapy firm said it would produce tens of millions of doses of AstraZeneca’s potential vaccine, AZD1222, for 18 months, which could be extended by a further 18 months into 2023.

It will be made at the firm’s three manufacturing suites at its new centre, Oxbox, in Oxford. Two of the suites will be ready to use in the next two months, earlier than expected. AstraZeneca will pay Oxford Biomedica £50m under the deal.

AstraZeneca, which is developing the vaccine with researchers at Oxford University, said its global manufacturing capacity was close to 3bn doses.

News of the deal came as AstraZeneca announced on Monday night that it had begun late-stage trials of the vaccine in the US, where it plans to enrol 30,000 adults, as part of a global programme to test the product on 50,000 people.

AstraZeneca, along with US company Pfizer and its German partner BioNTech which are also developing a coronavirus vaccine, have said they could have data by October to secure approval from US regulators for emergency use of their respective products.

Last week, scientists raised hopes that trials of the Oxford vaccine could have gathered enough data to show whether it works and is safe by the end of the year, before being submitted to UK regulators for approval.

Britain’s other big drugmaker, GlaxoSmithKline, is also developing a coronavirus vaccine in partnership with France’s Sanofi Pasteur that is due to go into human testing this month. The UK government has bought millions of doses of both vaccines, along with the one from BioNTech and Pfizer, and another one developed by France’s Valneva.

Last month, Russia approved a controversial Covid-19 vaccine – Sputnik V – for widespread use after less than two months of human testing. It said it would push ahead with large-scale manufacture, even though the World Health Organization said the vaccine should not be produced until it had completed phase 3 trials.

Those final trials, involving 40,000 people, began last Wednesday. Doctors and teachers will be among the first to be offered the jab on a voluntary basis starting this month while the shot will be mandatory for military personnel.

China has several potential coronavirus vaccines in late-stage testing and has been giving one of them to health workers and border officials under “emergency use” since July, according to a senior health official.